We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.30 | 0.19% | 158.26 | 159.14 | 158.11 | 158.11 | 6,293,906 | 00:00:00 |
By Chris Wack
AC Immune SA said it saw positive new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc.
The company said ACI-35.030 is the first Alzheimer's disease vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.
AC Immune said results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030.
Interim safety data further support ACI-35.030's favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.
As previously reported, the ongoing Phase 1b/2a study has been expanded to include a total of 24 Alzheimer's disease participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.
AC Immune shares were up 11% to $6.70 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 12, 2021 09:29 ET (14:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions